join 2rcep 2 (810 by 450)

Community groups oppose ISDS in TPP-11 talks as US dumps ISDS in NAFTA, and NZ also says no

November 6, 2017 “The Australian Government should oppose foreign investor rights to sue governments in the talks attempting to resurrect the TPP without the US later this week,” AFTINET Convener Dr Patricia Ranald said today.

The talks will take place in da Nang, Vietnam on November 8-9, ahead of the APEC meeting to be held on November 10.

TPP-11 still not agreed ahead of APEC deadline next week

November 2, 2017: Media reports from the secret TPP–11 meeting held in Japan this week show that there is still no agreement between the 11 governments about the possible content of the TPP agreement without the US. They were aiming to reach agreement before a TPP -11 Ministers’ meeting on November 8-9, ahead of the APEC meeting in Vietnam on November 10.

New paper explains TPP's impact on access to medicines in member countries

November 2, 2017: A new research paper, co-authored by public health experts Deborah Gleeson, Joel Lexchin, Ruth Lopert and Burcu Kilic, explains the impact that the intellectual property chapter of the original Trans-Pacific Partnership could have on access to medicines in each of the TPP countries. As the TPP-11 meet this week to attempt to revive the TPP without the US, the research findings show how damaging the original medicine proposals would be.

AFTINET welcomes Labor trade policy changes, but calls for clear rejection of unfair deals

October 30, 2017: The Australian Fair Trade network of community organisations welcomes the pledge by Shadow Trade Minister Jason Clare in his speech to ACCI today for the public release and independent economic analysis of trade agreements before they are signed, but there should also be health and environmental impact studies, AFTINET Convener Dr Patricia Ranald said today.

India responds to calls to resist medicine monopolies in RCEP

October 26, 2017: MSF (Doctors without Borders) has called for India and other countries to block RCEP proposals from Japan and South Korea that would allow pharmaceutical companies to have stronger monopolies, prevent competition and keep medicine prices high. They added that it was time to end the push for ever-higher levels of monopoly control of medicines through free trade agreements .

Pages